The Efficacy of Tranexamic Acid to Reduce Perioperative Blood Loss and Blood Transfusion in Patients Undergoing Distal Femur Fracture Surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220104001

Enrollment

Registered

2022-01-04

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distal Femur Fractures Intraoperative Blood Loss Distal Femur Fractures Blood Loss Tranexamic Acid

Interventions

Tranexamic acid 10 mg per kg intravenously 20 minutes before surgery,0.9 percent Sodium Chloride 10 ml intravenously 20 minutes before surgery

Active Comparator Drug,Placebo Comparator Drug

Tranexamic Acid,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Unilateral distal femur fracture 2. Operative management 3. Age between 20 to 65 years old 4. Closed fracture

Exclusion criteria

Exclusion criteria: 1. Bleeding disorders 2. Serum platelet count less than 150000 per cmm 3. Coagulopathy 4. Venous thrombosis 5. Allergic to Tranexamic Acid 6. Multiple injuries 7. Concomitant vascular injuries 8. Cerebral concussion 9. History of taking anticoagulants 10. Pregnancy

Design outcomes

Primary

Measure	Time frame
intraoperative blood loss intraoperative milliliters	—

Secondary

Measure	Time frame
VTE 24 hours after surgery By diagnosis	—

Countries

Thailand

Contacts

Public ContactAustin Supanaranond

Orthopedic Department, Chonburi Hospital

alongkornsup@gmail.com0869608670

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026